Lobomycosis in Inshore and Estuarine Dolphins
To the Editor: Lobomycosis is a chronic dermal infectious disease affecting humans and some species of dolphins but not, to date, freshwater dolphins. Because this disease is still considered rare despite the increasing number of reported cases in humans and cetaceans, clinical and epidemiologic information must be accurately reported to help clarify many of the unknown aspects of this disease.
We address this point because after carefully reading the excellent report by Elsayed et al. on the fi rst human case of lobomycosis in Canada, we noticed that the authors describe the natural disease as occurring in humans and marine and freshwater dolphins only (1) . However, this information is only partially correct because to date lobomycosis has not been described in freshwater dolphins. What is more worrisome is that this information is beginning to be referenced in other published articles (2) . So far, lobomycosis has been confi rmed in 2 species of inshore and estuarine Delphinidae: 1) the common bottlenose dolphin (Tursiops truncatus) from Brazil, the Atlantic coast of the United States, and Europe and 2) the Guiana dolphin (Sotalia guianensis) from the Surinam River estuary (3-8).
The fact that lobomycosis is endemic in humans in the Amazon basin could logically raise the suspicion that other animal species in this area may act as reservoirs or even be affected by the disease. However, the infection has never, to our knowledge, been reported in botos (Inia geoffrensis) or tucuxis (Sotalia fl uviatilis) from the Amazon and Orinoco Rivers. Preliminary fi eld studies, like the one carried out by da Silva et al., failed to demonstrate the disease in any of the 385 live-captured I. geoffrensis boto specimens from the Mamirauá Reserve in the central Amazon region of Brazil (9); similarly, our observational studies in the Venezuelan Orinoco River failed to detect the disease. On the other hand, despite the absence of indigenous cases of lobomycosis in humans reported in the United States, the disease is endemic in dolphins from the Indian River Lagoon in Florida (7), suggesting that no apparent epidemiologic link may exist between humans and cetaceans. Unfortunately, the etiologic agent of lobomycosis, Lacazia loboi ( Figure) , has not been cultured in vitro (10) despite exhaustive attempts, making its isolation from probable and suspected environmental sources impossible.
Dolphin-to-human transmission of lobomycosis has been reported only 1 time; the case-patient was an aquarium attendant who had had close physical contact with an affected dolphin (5). However, because the possibility of zoonotic transmission of this disease remains latent and because many pathologic and clinical aspects of the disease remain poorly understood, it is imperative to clarify these ecological concepts. Up-to-date molecular epidemiology studies to compare the strains affecting humans and dolphins and To the Editor: Contrary to early expectations, the co-occurrence of leprosy and HIV has not increased globally (1). However, most of the larger studies on the subject were conducted in the early to mid-1990s in African countries, and the research designs had limited power to describe the true effects of co-infection (1). Moreover, the introduction of highly active antiretroviral therapy (HAART), which has been used routinely in Brazil since 1996, altered the clinical evolution of HIV infection (2) and led to increasing reports of immune restoration infl ammatory syndrome (IRIS) associated with leprosy (3,4). Although some researchers have argued that this association may not affect public health (2), its true importance remains to be clarifi ed. Finally, leprosy has a wide range of clinical manifestations, which sometimes imposes a clinical challenge and may lead to misdiagnosis (5). Together, these factors may have helped mask the true scenario of leprosy and HIV co-infection, particularly in areas where these conditions are highly endemic. In this context, case reports from referral centers that refl ect the broad clinical aspects of leprosy and HIV co-occurrence are important to increase clinicians' awareness of both diseases.
We report 3 HIV-positive/AIDS patients who showed different clinical manifestations of leprosy; their conditions were diagnosed before and after HAART initiation. All patients lived in Manaus, the capital of the state of Amazonas in Brazil, an area where both leprosy and HIV infection are endemic. The 3 patients represent a sample from our 11-year experience (Figure) . There was decreased pain sensitivity in the
